CareDx, Inc. reported the first quarter ended March 31, 2026 results: revenue $118 million, net income $3 million, EPS $0.05. Guidance raised.
“for transplant patients and caregivers, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights · Revenue of $118 million, an increase of 39% year-over-year · Testing services revenue of $91 million, an increase of 48% year-over-year, and testing services volume of approximately 54,900, an increase”
Material Agreements
CareDx, Inc. entered into Merger Agreement with Naveris, Inc., Nautilus Merger Sub, Inc., and Shareholder Representative Services LLC valued at $160.0 million in cash, subject to certain customary adjustments, and up to $100.0 million in additi (effective 2026-04-28).
“On April 28, 2026, CareDx, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Naveris, Inc., a Delaware corporation (“Naveris”), Nautilus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), and Shareholder Representative Services LLC”
Earnings Releases
CareDx, Inc. reported first quarter of 2026 results: revenue approximately $118 million.
“Revenue of approximately $118 million, growth of 39% year-over-year”
Material Agreements
CareDx, Inc. entered into Purchase Agreement with Eurobio Scientific S.A. valued at $170 million in cash (effective 2026-04-15).
“On April 15, 2026, CareDx, Inc. (the “Company”) entered into a Purchase Agreement (the “Purchase Agreement”) with Eurobio Scientific S.A. (“Eurobio”), pursuant to which, and subject to the terms and conditions set forth therein, the Company agreed to sell to Eurobio the shares of CareDx AB, a wholly-owned Swedish subsidiary of the Company, and certain assets relating to the Company’s kitted laboratory products business and related software (the “Business”) for $170 million in cash”
Governance Changes
CareDx, Inc.: Changed voting standard for director elections from plurality to majority vote in uncontested elections and adopted a director resignation policy for incumbents who do not receive a majority vote (effective 2025-12-12).
“On December 12, 2025, the Board of Directors (the “Board”) of CareDx, Inc. (the “Company”) amended and restated the Company’s bylaws (the “Amended and Restated Bylaws”) to change the voting standard for the election of directors from a plurality to a majority voting standard, except in a contested election, where a plurality vote shall apply.”
Alexander Johnson departed as President of Patient and Testing Services at CareDx, Inc..
“On September 12, 2024, CareDx, Inc. (the “Company”) announced that the Company reached an agreement with Alexander Johnson, the Company’s President of Patient and Testing Services, pursuant to which Mr. Johnson’s employment would conclude effective as of September 13, 2024 and that such separation would be treated as a termination by the Company without “cause””
Keith Kennedy was appointed as Chief Operating Officer at CareDx, Inc..
“The Board of Directors of CareDx, Inc. (the “Company”) has appointed Keith Kennedy, as the Company’s Chief Operating Officer, effective September 12, 2024 (the “Effective Date”).”
Earnings Releases
CareDx, Inc. reported the first quarter ended March 31, 2024 results: revenue $72.0 million, net income net loss was $16.7 million, EPS $0.32. Guidance raised.
“CareDx, Inc. (Nasdaq: CDNA) — today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights • Reported first quarter revenue of $72.0 million. • Revenue for Testing Services of $53.8 million, an increase of 15% as compared to the fourth quarter 2023. • Grew testing services patients results for the third consecutive”
John W. Hanna was appointed as Class III director at CareDx, Inc..
“The Board of Directors (the “Board”) of CareDx, Inc. (the “Company”) has appointed John W. Hanna as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective April 15, 2024 (the “Effective Date”).”
John W. Hanna was appointed as President and Chief Executive Officer at CareDx, Inc..
“The Board of Directors (the “Board”) of CareDx, Inc. (the “Company”) has appointed John W. Hanna as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective April 15, 2024 (the “Effective Date”).”
R. Bryan Riggsbee was appointed as Director at CareDx, Inc..
“On March 9, 2024, the board of directors (the “Board”) of CareDx, Inc. (the “Company”) appointed R. Bryan Riggsbee as a Class II director of the Company, effective March 11, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.